<DOC>
	<DOCNO>NCT00187291</DOCNO>
	<brief_summary>The ABCD clinical study design determine T-Wave Alternans ( TWA ) test equivalent Electrophysiology Study ( EPS ) predict life-threatening heart rhythm patient ischemic heart disease , leave ventricular dysfunction , non-sustained tachycardia . Patients undergo TWA test EP study receive Implantable Cardioverter Defibrillator ( ICD ) either test show patient risk . The patient follow 2 year . The incidence ventricular tachyarrhythmia event total mortality evaluate duration study .</brief_summary>
	<brief_title>Study Compare TWA Test EPS Test Predicting Patients Risk Life-threatening Heart Rhythms ( ABCD Study )</brief_title>
	<detailed_description>The primary objective study test hypothesis therapy direct primarily T wave alternans ( TWA ) test , measure non-invasively exercise , equivalent therapy direct electrophysiological study ( EPS ) predict spontaneous ventricular tachyarrhythmic event ( VTEs ) patient ischemic heart disease , leave ventricular dysfunction , asymptomatic non-sustained ventricular tachycardia ( NSVT ) . In absence previous life-threatening ventricular arrhythmia ( i.e. , primary prevention ) , ICD implantation currently indicate patient ischemic heart disease , leave ventricular dysfunction , asymptomatic non-sustained ventricular tachycardia , positive EPS . The objective study demonstrate TWA test direct therapy equivalent EPS direct therapy guide ICD implantation purpose primary prevention sudden cardiac death ( SCD ) patient ischemic heart disease , leave ventricular dysfunction , asymptomatic non-sustained ventricular tachycardia . This prospective , multi-center study demonstrate following : PRIMARY HYPOTHESIS : TWA test direct therapy equivalent EPS direct therapy predict VTEs patient ischemic heart disease , LVEF le 0.40 , asymptomatic non-sustained ventricular tachycardia . The study determine whether positive predictive value TWA test direct therapy equivalent positive predictive value EPS direct therapy . The study also determine whether negative predictive value TWA test direct therapy equivalent negative predictive value EPS direct therapy . The positive group TWA test direct therapy compare positive group EPS direct therapy , negative group TWA direct therapy compare negative group EPS direct therapy . SECONDARY HYPOTHESIS : The study determine whether positive predictive value TWA test ( include indeterminates ) equivalent positive predictive value EPS predict future VTEs . The study also determine whether negative predictive value TWA test ( include indeterminates ) equivalent negative predictive value EPS predict future VTEs . The TWA test positive group compare EPS positive group , TWA test negative group compare EPS negative group . The secondary hypothesis also test primary endpoint define .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients previous history life threaten ventricular arrhythmia symptomatic nonsustained VT , meet follow inclusion criterion may enrol study : 1 . Ischemic heart disease document follow : previous myocardial infarction ( document 2 3 following : history , ECG , and/or cardiac enzyme ) , prior PTCA CABG ; angina positive exercise pharmacological stress test ; angina great 50 % occlusion coronary artery , leave ventricular dysfunction attribute angiographically document coronary artery disease 2 . LVEF le 0.40 determined echocardiography , radionuclide contrast ventriculography within six month enrollment . 3 . Nonsustained ventricular tachycardia within 6 month enrollment , define great 3 consecutive premature ventricular contraction least three consecutive interval cycle length 550 m , entire episode lasting le 30 second . This episode associate either symptom , palpitation alone . An episode NSVT associate symptom ( palpitation ) satisfy inclusion criterion trial . 4 . The patient 18 year age old . 5 . In judgement principal investigator , patient capable undergoing submaximal treadmill exercise test heart rate 120 bpm . 6 . The patient sign late IRB approve informed consent form . Patients meet follow exclusion criterion eligible enrollment : 1 . The patient unable give inform consent . 2 . The patient know cardiac arrest sustain life threaten ventricular arrhythmia , set acutely reversible cause ( e.g. , acute phase MI , drug intoxication ) . 3 . The patient EPS TWA test time reason prior screen consented trial . 4 . The patient unstable coronary artery disease . 5 . The patient contraindication ICD implantation . 6 . A submaximal exercise test contraindicate . 7 . The patient persistent atrial fibrillation flutter . 8 . The patient le 28 day post MI , post CABG , post coronary angioplasty . 9 . The patient LVEF 0.40 , evidence ischemic heart disease define section 4.1 . 10 . The patient NYHA functional Class IV congestive heart failure symptom time enrollment . 11 . The patient class 1 3 antiarrhythmic drug . 12 . The patient participate study another investigational device drug . If , opinion investigator , would interfere study , eligibility patient discuss primary investigator ABCD trial , Drs . Rosenbaum Costantini . 13 . The patient significant medical condition acute illness opinion investigator precludes participation . 14 . The patient previous history syncope , unless episode clearly cause ventricular tachyarrhythmia . 15 . The patient life expectancy le one year cause . 16 . The patient positive pregnancy test . 17 . The patient geographically stable unable comply follow schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>T-Wave Alternans</keyword>
	<keyword>ICD</keyword>
	<keyword>Primary Prevention</keyword>
</DOC>